HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy
Author:
Funder
Swiss Tumor Institute
Publisher
Public Library of Science (PLoS)
Subject
Multidisciplinary
Reference42 articles.
1. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells;R Nahta;Cancer Res,2005
2. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand—receptor interactions;I Alroy;FEBS Lett,1997
3. Her-2/ neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment;G Hudelist;Br J Cancer,2003
4. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease;MA Cobleigh;J Clin Oncol,1999
5. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy;JS Ross;Oncologist,1998
Cited by 24 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes;JMIR Cancer;2024-04-04
2. HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results;Breast Cancer Research;2023-12-14
3. HER2-directed biosimilar Ogivri® in the treatment of breast cancer: real-world reporting of symptoms and well-being using electronic patient-reported outcome (ePRO): results of the OGIPRO study (Preprint);2023-11-01
4. A review of HER2 overexpression and somatic mutations in cancers;Critical Reviews in Oncology/Hematology;2023-06
5. A Review and Meta-analysis on Trastuzumab Resistance in Patients with HER2+ Breast Cancer;Mini-Reviews in Medicinal Chemistry;2023-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3